Skip to main content

Table 1 Effectiveness of a single oral dose of a novel chewable tablet (Credelio Plus) containing milbemycin oxime and lotilaner against induced L4 larval and immature adult (L5) Ancylostoma caninum infections in dogs

From: Effectiveness of a novel orally administered combination drug product containing milbemycin oxime and lotilaner (Credelio® Plus) for the treatment of larval and immature adult stages of Ancylostoma caninum in experimentally infected dogs

Study Stage at time of treatment Day of inoculation a Day of treatment Day of necropsy (worm recovery) Treatment group n No. of infected dogs Worm count range Geometric worm count Effectiveness compared to vehicle control
% efficacy Effectiveness P-value
1 L4 Larvae 0 7 12 Vehicle control 8 8 60–248 171.9
      Credelio Plusb 8 8 1–15 4.6 97.3 P < 0.001
      Credelioc 8 8 98–236 171.7 0.1 P < 0.001
2 L4 Larvae 0 7 12 Vehicle control 10 10 42–156 79.4
      Credelio Plusb 10 3 0–2 0.3 99.6 P < 0.001
1 Immature adult (L5) 0 11 16 Vehicle control 8 8 173–255 198.7
      Credelio Plusb 8 6 0–86 2.5 98.7 P < 0.001
      Credelioc 8 8 149–231 178.8 10.0 P < 0.001
2 Immature adult (L5) 0 11 16 Vehicle control 10 10 61–302 109.7
      Credelio Plusb 10 2 0–3 0.3 99.7 P < 0.001
  1. n Number of animals per group
  2. aEach dog was inoculated with ca. 300 L3 A. caninum
  3. bCredelio Plus provided minimum dosages of 0.845 to 0.943 mg/kg of milbemycin oxime in both studies
  4. cCredelio™ (lotilaner mono product) was included in study 1 to assess non-interference